Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combinatio

[News]

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab®-paclitaxel (ABRAXANE® for Injectable Suspension) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer.

More... (http://www.news-medical.net/news/20100419/Updated-survival-data-from-Phase-III-trial-of-nab-paclitaxel-gemcitabine-combination-for-pancreatic-cancer.aspx)